Brief: Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense
06/10/2026 21:57
BRIEF-Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense Oct 6 (Reuters) - BioMarin Pharmaceutical Inc. BMRN.O:
BIOMARIN PHARMACEUTICAL - EXPECTS Q3 2026 PRE-TAX CHARGES OF $283 MILLION FOR BOUGHT IPR&D EXPENSE - SEC FILING
BIOMARIN PHARMACEUTICAL - EXPECTS $1.5 UNFAVORABLE IMPACT TO GAAP AND NON-GAAP DILUTED EPS FOR Q3 2026 - SEC FILING
BIOMARIN PHARMACEUTICAL - EXPECTS TOTAL PRE-TAX CHARGES OF $320 MILLION FOR FULL YEAR 2026 FROM ALESTA ACQUISITION - SEC FILING
BIOMARIN PHARMACEUTICAL - EXPECTS $1.55 UNFAVORABLE IMPACT TO GAAP AND NON-GAAP DILUTED EPS FOR FULL YEAR 2026 - SEC FILING
Source text: [ID:n0001048477-26-000019]
Further company coverage: BMRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioMarin Pharmaceutical
See all newsUS RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Brief: Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense
Brief: Biomarin Appoints Cara Bauer As Chief People Officer
Brief: Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026
U.S. STOCKS ON THE MOVE-GitLab, California utilities, Herbalife